Unity Biotechnology Inc (NASDAQ:UBX) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 4,910,000 shares, an increase of 5.8% from the October 31st total of 4,640,000 shares. Currently, 23.0% of the shares of the stock are sold short. Based on an average daily volume of 278,100 shares, the days-to-cover ratio is currently 17.7 days.
Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new position in Unity Biotechnology during the third quarter worth approximately $45,000. Bank of Montreal Can grew its position in Unity Biotechnology by 164,400.0% during the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock worth $47,000 after buying an additional 4,932 shares in the last quarter. Aperio Group LLC bought a new position in Unity Biotechnology during the 2nd quarter worth $50,000. Squarepoint Ops LLC bought a new position in Unity Biotechnology in the 3rd quarter valued at about $82,000. Finally, Ellington Management Group LLC bought a new position in Unity Biotechnology in the second quarter valued at approximately $103,000. 35.56% of the stock is currently owned by institutional investors and hedge funds.
Shares of UBX opened at $7.19 on Friday. The stock has a 50 day simple moving average of $6.98 and a 200 day simple moving average of $7.32. Unity Biotechnology has a 52-week low of $5.61 and a 52-week high of $17.46. The firm has a market capitalization of $330.32 million, a PE ratio of -2.83 and a beta of 0.02.
Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.54) earnings per share for the quarter, missing analysts consensus estimates of ($0.49) by ($0.05). As a group, research analysts anticipate that Unity Biotechnology will post -2 EPS for the current fiscal year.
Several equities research analysts have recently commented on UBX shares. Cantor Fitzgerald reissued an overweight rating on shares of Unity Biotechnology in a research note on Thursday, October 17th. Zacks Investment Research downgraded Unity Biotechnology from a hold rating to a sell rating in a report on Saturday, October 12th. Finally, Mizuho restated a buy rating and set a $33.00 target price on shares of Unity Biotechnology in a report on Monday, November 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $19.50.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
Featured Article: Day Trading
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
More:
Unity Biotechnology Inc (NASDAQ:UBX) Short Interest Update - Riverton Roll
Recommendation and review posted by G. Smith
